A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection  by Rodriguez-Del Rio, Estela et al.
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In the  search  for an  effective  vaccine  against  the  human  pathogen,  Listeria  monocytogenes  (Listeria),  gold
glyconanoparticles  (GNP)  loaded  with  a listeriolysin  O  peptide  LLO91–99 (GNP-LLO)  were  used  to immunise
mice,  initially  using  a dendritic  cell  (DC)  vaccine  approach,  but subsequently  using a standard  parenteral
immunisation  approach.  To  enhance  vaccine  immunogenicity  a novel  polysaccharide  adjuvant  based
on delta  inulin  (AdvaxTM) was  also  co-formulated  with  the  GNP  vaccine.  Conﬁrming  previous  results,
DC  loaded  in  vitro  with GNP-LLO  provided  better  protection  against  listeriosis  than  DC  loaded  in  vitro
using  free  LLO  peptide.  The  immunogenicity  of GNP-LLO  loaded  DC  vaccines  was further  increased  by
addition  of AdvaxTM adjuvant.  However,  as  DC  vaccines  are  expensive  and  impracticable  for  prophylac-
tic  use,  we next  asked  whether  the  same  GNP-LLO  antigen  could  be  used  to directly  target  DC  in  vivo.
Immunisation  of  mice  with  GNP-LLO  plus  AdvaxTM adjuvant  induced  LLO-speciﬁc  T-cell  immunity  and
protection  against  Listeria  challenge.  Protection  correlated  with  an  increased  frequency  of  splenic  CD4+
+ +and  CD8 T cells,  NK  cells  and  CD8 DC,  and  Th1  cytokine  production  (IL-12,  IFN-,  TNF-,  and  MCP-1),
post-challenge.  Enhanced  T-cell  epitope  recruitment  post-challenge  was  seen  in the groups  that  received
AdvaxTM adjuvant.  Immunisation  with  GNP-LLO91–99 plus  AdvaxTM adjuvant  provided  equally  robust  Lis-
teria  protection  as  the best  DC  vaccine  strategy  but without  the  complexity  and  cost, making  this  a  highly
velop
ublispromising  strategy  for de
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. IntroductionCandidate prophylactic vaccines against Listeria monocytogenes
Listeria) include live attenuated pathogens [1–4], live vector-based
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approaches [5–7] and subunit vaccines [8,9]. However, the use of
live vaccines in at-risk immunocompromised individuals including
pregnant women poses major safety risks, making a non-living sub-
unit vaccine a more preferable approach. Unfortunately, subunit
vaccines by themselves are generally ineffective due to overall poor
immunogenicity and inability, in particular, to generate the T-cell
immunity required for protection against intracellular organisms
such as Listeria.
Dendritic cell (DC) vaccines are produced by isolation of DC from
a subject, in vitro loading of the DC with the relevant vaccine anti-
gen, and then intravenous or subcutaneous injection of the live DC
back into the subject. Based on their improved ability to induce
T-cell immunity, DC vaccines have been proposed as solutions for
induction of T-cell protection against intracellular infections, such
as HIV [10]. Our group previously reported a DC vaccine loaded with
a peptide from the Listeria protein, glyceraldehyde 3-phosphate
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ehydrogenase (GAPDH), induced generation of GAPDH-speciﬁc
D8+ and CD4+ T cells and conferred protection against Listeria [11],
onsistent with the importance of T-cell responses against GAPDH
n Listeria protection [12–14]. Other Listeria antigens that contain
D4+ and CD8+ T-cell epitopes and that might therefore enhance
he efﬁcacy of a DC-based Listeria vaccine include listeriolysin (LLO),
ctA, and p60 [11,15,16]. To date, only T-cell immunity against LLO
as been reported in humans recovering from listeriosis [17], sug-
esting a potential role of in protection. We  therefore wished to
est whether a T-cell vaccine targeting LLO could protect against
isteriosis. In particular, we sought to test whether a nanoparticle-
onjugated LLO peptide could increase DC vaccine efﬁcacy [10,18]
nd also whether a novel T-cell adjuvant could enhance LLO vaccine
mmunogenicity [19]. Gold glyconanoparticles (GNPs) constitute
 nanoscale metallic core to which self-assembled monolayers
f carbohydrate ligands are covalently linked by means of thiol
hemistry [20]. Due to their water dispersibility, biocompatibil-
ty, resistance to enzymatic degradation, ease of preparation, and
bility to incorporate different ligands, GNPs are highly versatile
21,22]. In this study, therefore, we sought to test the potential of a
lucose-labelled GNP presenting the LLO91–99 peptide (GNP-LLO) to
rotect against listeriosis in a murine model. In the ﬁrst approach,
e sought to apply the previous approach of loading DC in vitro
sing the GNP-LLO carrier prior to injection of the DC back into the
nimals. However, given the logistical difﬁculties of the DC vaccine
pproach, we also wished to test whether, rather than being used
or DC vaccine loading in vitro, the GNP-LLO antigen could be used
or parenteral immunisation along the lines of a traditional vaccine.
Given the poor T-cell responses induced by subunit vac-
ines, we sought to further enhance GNP-LLO immunogenicity
y use of AdvaxTM, a novel polysaccharide adjuvant derived
rom microparticles of delta -d-[2-1]poly(fructo-furanosyl)-d-
lucose (delta inulin) [25]. In animal models AdvaxTM has been
hown to enhance cellular plus humoral immunity against a broad
pectrum of antigens including inﬂuenza [26], Japanese encephali-
is [27], West Nile virus [28], hepatitis B [29], and HIV [30] vaccines.
dvaxTMhas also been shown effective and safe in human trials of
andemic inﬂuenza [31] and hepatitis B [29], vaccines.
. Methods
.1.1. Peptides and adjuvants
We  used as immunogens, peptides representing known Lis-
eria T cell epitopes, namely GAPDH1–22, LLO91–99 and LLO189–201
6,11,15]. Immunisation with free LLO189–200 and LLO190–201 pep-
ides has previously been shown to induce CD4+ T cell responses
n mice but did not confer Listeria protection [11,32]. All peptides
ere synthesised at CNB, CSIC, Madrid followed by high perfor-
ance liquid chromatography (HPLC) and mass spectrometry using
 MALDI-TOF ReﬂexTM IV mass spectrometer (Bruker Daltonics,
remen, Germany). Peptide purity was >95% after HPLC. AdvaxTM
djuvant (Adv1) was supplied by Vaxine (Adelaide, Australia)
31,33–35], and was mixed with antigen by simple admixture
mmediately before immunisation of mice.
.1.2. Bacteria
L. monocytogenes 10403S strain (LMWT) was obtained from D.A.
ortnoy (University of California, Berkeley, CA, USA).
.1.3. Preparation of gold glyconanoparticles bearing LLO91–99
eptides (GNP-LLO91–99)
LLO91–99 peptide with a C-terminal cysteamide (LLO91–99C(O)
HCH2CH2SH, 14 mg,  purity 95%) was purchased from GenScriptine 33 (2015) 1465–1473
and 5-(mercapto)pentyl--d-glucopyranoside (GlcC5SH) was  pre-
pared as reported in the literature [36]. GNP preparation is included
in Supplemental information. Average gold diameter 1.5 ± 0.5 nm
(the size histogram in Fig. S1, panel A was obtained by counting
600 particles in the TEM image).
2.1.4. Preparation of DC vaccines
Bone-marrow DC were differentiated with GM-CSF, and CD11c+
cells isolated with anti-mouse CD11c-coated magnetic beads and
MACS separation columns (Miltenyi Biotech Inc., Auburn, CA)
[6,11] from 8 to 12 week-old female CD1, Balb/c or C57BL/6
mice. Bone marrow macrophages (DM) were obtained from same
femurs and differentiated with M-CSF, as described [11]. DC used
were MHC-II+CD11c+CD40+CD11b+/−CD86+/−F4/80−Gr-1− and of
DM were CD11b+MHC-II+F4/80+/−CD11c−Gr-1−CD40−CD86−. Cul-
tured DC were ex vivo loaded with 50 g/ml GAPDH1–22, LLO91–99
or LLO189–201 peptides or with 5 g/ml of GNP-LLO91–99 for 24 h.
Cells were analysed for apoptosis by FACS analysis using annexin-
V-APC and H-1770 (BD-Biosciences), for cell viability with Trypan
blue staining, and cell surface markers by FACS.
2.1.5. T-cell assays
T-cell analysis, cytotoxic T lymphocytes responses and delayed
type hypersensitivity (DTH) analysis are described in Supplemental
information.
2.1.6. Preparation of peptide-coupled GNP vaccines
GNP carrying approximately 90% glucose and 10% LLO91–99 (Fig.
S1, panel A) were prepared by reduction in situ of Au(III) salt with
sodium borohydride, as described [21,37]. The ligands (LLO91–99
peptide and glucose) were derivatised with thiol-ending linkers to
attach them to the gold core (Fig. S1, panel A). 5-Mercaptopentyl
-d-glucopyranoside (GlcC5SH) with a short aliphatic linker, as
previously reported [36] was used as a ligand partner to control
the density of LLO91–99 peptide on the GNPs. Glucose is ideal to con-
fer water dispersibility and biocompatibility to the GNPs without
interfering with the antigenic properties of LLO91–99 peptide [24].
LLO peptides and GNP-LLO91–99 did not adversely affect DC viabil-
ity or promote apoptosis (Fig. S1, panel B and DC column in Table
S1). They were also well tolerated at 50 g/ml concentrations in
C57BL/6, CD-1 or Balb/c mice strains, (C57BL/6 column in Table S1),
while at 500 g/ml concentrations they caused decreased DC via-
bility and increased IL-1 concentration suggesting potential toxicity
(Table S1)  [38].
2.1.7. GNP immunogenicity assessment
We  immunised mouse footpads with 0.1 g of recombinant LLO
(LLOrec) and then evaluated T-cell proliferative recall responses to
in vitro stimulation with LLO91–99, LLO189–201, GNP-LLO91–99, LMWT
lysate (LM-lysate) or LLOrec at doses ranging from 0 to 500 g/ml. T-
cell proliferation was  dose dependent peaking at 50 g/ml and then
declining for all antigens (Fig. S1, panel C). GNP-LLO91–99 induced
a high level of T-cell proliferation equivalent to LM-lysate (Fig. S1,
panel C). LLO91–99 and LLOrec induced the next best T-cell prolifera-
tion, while LLO189–201 was lowest. To test whether the higher T-cell
recall responses with GNP-LLO91–99 might reﬂect improved MHC-I
antigen processing by lymph node APC, we  compared MHC-I pep-
tide presentation after ex vivo loading of DC or DM with LLO91–99
or GNP-LLO91–99. MHC-I molecules were immuno-precipitated and
levels of LLO peptides bound to MHC-I assessed by western-blot
using rabbit anti-LLO antibodies, as previously reported for MHC-II
molecules [5,11]. GNP-LLO91–99 resulted in higher efﬁciency load-
ing than free LLO91–99 peptides of MHC-I molecules on either DC or
 / Vaccine 33 (2015) 1465–1473 1467
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Fig. 1. Ex vivo loading of DC vaccines and T cell responses. (A) T-cell proliferation in
response to stimulation in vitro with 50 g/ml of LLO91–99 in popliteal lymph node
homogenates 7 days after footpad inoculation with 1 × 105 cells of DC vaccines or
saline (NT) [14]. Results show the mean ± SD of the stimulation index calculated
as  ratio of proliferation in active wells/proliferation of control samples in triplicate
3E. Rodriguez-Del Rio et al.
M (Fig. S1, panel D), with far higher presentation by DC than DM
Fig. S1, panel D).
.1.8. Ex vivo activation of DC vaccines
We  examined the effect of LLO peptide carriers on DC vaccine
ctivation [6,10]. Activated DC show a characteristic CD11c+MHC-
I+CD40+CD86+ phenotype [10,18]. To examine DC activation by
LO carriers, at day 5 after GM-CSF differentiation, DC were puri-
ed as CD11c+ cells using MACS magnetic beads (Miltenyi) and
oaded ex vivo for 24 h with 5 g/ml of GNP-LLO91–99 in pres-
nce or absence of AdvaxTM adjuvant (50 g/ml) or with 50 g/ml
f LLO91–99, LLO189–201, LM-lysate or left untreated (DC-CONT).
ext, the frequency of CD11c+MHC-II+ cells positive for CD40+
r CD86+ DC was assessed as markers of mature and activated
C (Fig. S2, panel A). DC-Listeria lysate induced the highest fre-
uency of MHC-IIhigh DC followed by GNP-LLO91–99 with or without
dvaxTM, which were both signiﬁcantly higher than LLO189–201 (Fig.
2, panel B). A similar picture was seen for CD11c+MHC-II+CD40+
r CD11c+MHC-II+CD86+ DC. Differences between GNP loaded and
ree peptide were even more marked when we analysed the fre-
uency of CD40+CD86+ double positive DC (Fig. S2, panel C).
.1.9. Immunisation
DC vaccines loaded in vitro using either free peptide or GNP-
onjugated peptides are indicated by placement of “DC” in front of
he speciﬁc antigen. If the name of the vaccine does not contain
GNP” then this means DC loading or immunisation was done with
ree peptide. Vaccines used were either DC vaccines (DC-LLO91–99,
C-LLO189–201, DC-GAPDH1–22, DC-GNP-LLO91–99, all at doses of
 × 106 DC per immunisation), or standard vaccines (GNP-LLO91–99
t 5 g per immunisation). Standard vaccines were administered
ith or without AdvaxTM adjuvant (250 g per immunisation).
ice were immunised intra-peritoneally (i.p) (n = 5), intravenously
n the tail vein (i.v) (n = 5) or left non-vaccinated (NV). Seven days
fter immunisation mice were challenged i.p or i.v with 5 × 103 CFU
f Listeria microorganisms/mouse [2]. Sera were stored at −80 ◦C
o measure cytokines by FACS analysis. At termination spleens and
ivers were homogenised and Listeria colony forming units (CFUs)
ounted in blood agar plates.
.1.10. Frequencies of CD8+-LLO91–99 speciﬁc T cells
To conﬁrm the frequency of IFN- producing LLO91–99 speciﬁc
D8T cells we used recombinant soluble dimeric mouse H-2Kb:Ig
for C57BL/6 mice) or H-2Kd:Ig (for Balb/c mice) fusion proteins fol-
owing the manufacturer’s instructions (DimerX I; BD Bioscience)
nd as previously described [2,11].
.1.11. Ethics statement
This study was carried out in accordance with the Guide for
he Care and Use of Laboratory Animals of the Spanish Ministry
f Science, Research and Innovation. The Committee on the Ethics
f Animal Experiments of the University of Cantabria approved the
rotocol (Permit Number: 2012/06) that follows the Spanish leg-
slation (RD 1201/2005). All surgery was performed under sodium
entobarbital anaesthesia, and all efforts were made to minimise
uffering..1.12. Statistical analysis
For statistical analysis, Student’s t test was applied. ANOVA
nalysis was applied to cytokine measurements. P ≤ 0.05 was(P  < 0.05). (B) Mice were immunised i.p with 5 × 10 CFU of Listeria/mice and 7 days
later DTH assays performed. Results are expressed as the mean difference± SD of
footpad swelling at 24 and 48 h inactive and control limbs, representative example
of  three independent experiments (P < 0.05).
considered signiﬁcant. GraphPad software was used for generation
of graphs.
3. Results
3.1. DC vaccines loaded using GNP-peptide carriers induce T-cell
proliferative responses against Listeria
Dendritic cells stimulate both CD4+ and CD8+ T cells in listerio-
sis [14]. To evaluate whether dendritic cell (DC) vaccines loaded
using GNP-peptide carriers might be more efﬁcient in inducing
T-cell responses than DC loaded using free peptides, mice were
immunised with DC that had been loaded in different ways. Seven
days post-immunisation, popliteal lymph nodes were stimulated
in vitro with LLO91–99 peptide and antigen-speciﬁc T-cell prolife-
rative responses measured. Immunisation with DC loaded in vitro
with GNP-LLO91–99 induced higher T-cell proliferation responses
than immunisation with DC loaded using free LLO91–99 peptide,
indicating the importance for induction of T-cell memory of attach-
ment of the LLO91–99 peptide to the GNP to enable efﬁcient loading
of DC vaccines. DC loaded in vitro with GNP-LLO91–99 induced
1  / Vaccine 33 (2015) 1465–1473
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Table 1
Frequencies of LLO91–99-CD8+ T cells induced by DC vaccines. Splenocytes of vacci-
nated mice incubated with recombinant dimeric H-2Kb:Ig fusion protein loaded
with LLO91–99 peptide. Frequencies of CD8+-LLO91–99 and IFN- producers were
performed as described in Section 2.1.10. Results are expressed as the mean ± SD
(P  < 0.05).
Vaccination type % Total dimer-
CD8/LLO91–99
% Gated dimer-
CD8/LLO91–99
DC-LM-lysate 0.05 ± 0.01 0.48 ± 0.01
DC-LLO91–99 0.06 ± 0.01 1.22 ± 0.02
DC-GNP-LLO91–99 0.17 ± 0.02 3.42 ± 0.02
vaccine, DC-GNP-LLO91–99 (Fig. 3B). This suggests that providing468 E. Rodriguez-Del Rio et al.
n equivalent T-cell proliferative response to a whole Listeria
ysate, consistent with efﬁcient DC loading and induction of T-cell
esponses by the GNP-peptide carrier (Fig. 1A). DC loaded with a
D4+ restricted epitope (LLO189–201) [11], failed to induce a T-cell
roliferative response, suggesting the DC vaccines preferentially
nduce a CD8+ T-cell response.
.2. DC vaccines loaded using GNP-peptide carriers induce DTH
esponses in Listeria-sensitised mice
Next, we examined the delayed type hypersensitivity (DTH)
esponse to the DC vaccines in previously Listeria-sensitised mice
s an in vivo measure of the ability of the different DC vaccines
o induce T-cell activation. The aim was to evaluate whether DC
oaded in vitro with GNP-LLO91–99 when injected into the foot-
ad of previously sensitised mice would trigger a typical Th1-type
-cell response as measured by DTH [7]. We  injected Listeria sensi-
ised mice in the footpad with DC loaded in vitro with LLO91–99 or
LO189–201 free peptides or with GNP-LLO91–99. In fact, DC loaded
ith LLO189–201 generated greater DTH responses in the sensitised
ice than DC loaded with LLO91–99 or GNP-LLO91–99, suggesting
hat LLO189–201 is normally a dominant T-cell epitope after Listeria
nfection (Fig. 1B). Interestingly, the DTH response to DC loaded
ith GNP-LLO91–99 in the presence of AdvaxTM adjuvant was sim-
lar in size to the DC-LLO189–201 response suggesting the LLO91–99
pitope could be turned into a dominant epitope, providing it was
resented by DC at a sufﬁciently high level together with sufﬁ-
ient co-stimulatory molecule expression induced by the AdvaxTM
djuvant (Fig. 1B).
.3. Immunisation with GNP-loaded DC vaccines provides
rotection of mice against listeriosis
We  next assessed protection against listeriosis using the
ifferent DC vaccine vectors, DC-LLO91–99, DC-LLO189–201, DC-
APDH1–22, DC-Listeria lysate, DC-GNP-LLO91–99, and empty DCs
DC-CONTROL) when compared to immunisation with free GNP-
LO91–99. DC-GAPDH1–22 was included as a positive control since it
reviously showed good Listeria protection [11]. Mice were immu-
ised i.v with a single dose of vaccine. Although i.v is an unusual
mmunisation route for standard vaccines, it is a typical route
or administration of cellular DC vaccines [6]. Seven days post-
mmunisation the mice were administered a live Listeria challenge.
ive days post-challenge, all mice were sacriﬁced and livers and
pleens recovered to count Listeria colony forming units (CFU) and
nalyse the immune cell populations. DC-GAPDH1–22 and DC-GNP-
LO91–99 provided the greatest Listeria protection (∼97 and 99% CFU
eduction, respectively), followed by DC-LLO91–99 (∼94%) (Fig. 2A).
C-LLO189–201 conferred no signiﬁcant protection (5%). Notably,
mmunisation of mice with free GNP-LLO91–99 (as opposed to DC
re-loaded in vitro with GNP-LLO91–99) conferred intermediate pro-
ection (∼60% CFU reduction). Control non-vaccinated mice (NV)
ere not protected and as expected had enlarged spleens and gran-
lomatous livers post-challenge (Fig. 2A, right hand ﬁgure).
.4. Immunisation with GNP-loaded DCs increases the frequency
f DC and CD8T cells in the spleen post-challenge
Protection in listeriosis is typically reﬂected by increases in the
requency of splenic macrophages (MØ), natural killer cells (NK),
ature DC and activated T cells post Listeria challenge [14,39].
e therefore examined the cell populations in the spleens ofmmunised mice 5 days post-challenge. Mice immunised with DC-
LO91–99, DC-GAPDH1–22, DC-GNP-LLO91–99 or free GNP-LLO91–99
articles showed an increased frequency of mature DC (70% of
ositive cells), CD8+ T cells (∼32% of positive cells), MØ (18–19%GNP-LLO91–99 0.05 ± 0.01 0.35 ± 0.01
GNP-LLO91–99 + Advax 0.20 ± 0.01 3.21 ± 0.02
of positive cells) and NK (10% of positive cells) in their spleens,
post-challenge. Only DC-LLO189–201 and DC-GAPDH1–22 immunised
mice showed an increased frequency of CD4+ T cells post-challenge
(Fig. 2B).
3.5. Listeria protection by GNP-loaded DC is associated with an
enhanced Th1 T-cell response
We  next evaluated whether Listeria protection of immunised
mice was associated with enhanced Th1 cytokine production,
as would be predicted for protection against an intracellular
bacterium. Immunisation with DC-LLO91–99, DC-GAPDH1–22, DC-
GNP-LLO1–99 and, to a lesser extent, free GNP-LLO91–99 was
associated with high levels of MCP-1, TNF- and IFN- produc-
tion, consistent with a strong Th1 response (Fig. 2C). However,
only DC-GAPDH1–22 and DC-GNP-LLO1–99 immunisation was asso-
ciated with measurable IL-12 production, post-challenge, (Fig. 2C),
which correlated with these groups having the greatest Listeria
protection (Fig. 2A) [6,11]. Next, we compared the ability of the
different vaccines to induce LLO-speciﬁc T-cell immunity. DC-GNP-
LLO91–99 induced a higher frequency of LLO-speciﬁc IFN-+ CD8+
T cells (3.42%), than induced by DC-LLO91–99 (1.22%), (Table 1).
The response induced by DC-GNP-LLO91–99 thereby compared
favourably to the 4.2% frequency of LLO-speciﬁc CD8+ T cells
obtained with the most protective Listeria vaccine we  had identiﬁed
to date, DC-GAPDH1–22, [11].
3.6. AdvaxTM adjuvant enhances Listeria protection by
GNP-LLO91–99
DC vaccines are expensive and impracticable. However,
standard immunisation with free GNP-LLO91–99 vaccine only
provided intermediate levels of Listeria protection, (∼60% CFU
reduction, Fig. 2), that was  inferior to the protection obtained with
the DC vaccines. We  wished to test, therefore, whether formula-
tion of GNP-LLO91–99 with AdvaxTM adjuvant might enhance its
ability to protect when administered through a traditional vaccine
approach. Mice immunised i.p with a single dose of GNP-LLO91–99
plus AdvaxTM did indeed exhibit enhanced protection (84%) when
compared to mice immunised with GNP-LLO91–99 alone (60%)
(Fig. 3A). This thereby achieved comparable levels of Listeria pro-
tection to those previously only achieved with the DC vaccine
approach.
Analysis of spleen populations 5 days post-challenge conﬁrmed
that i.p immunisation with GNP-LLO91–99 plus AdvaxTM adjuvant,
induced a similar frequency of mature DC, CD8+ T cells and NK cells
and a higher frequency of CD4+ T cells when compared to the DCit was  formulated with AdvaxTM adjuvant, standard immunisa-
tion with GNP-LLO91–99 was as good or better at inducing T-cell
responses and protection against Listeria than the much more com-
plex DC vaccine approach.
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Fig. 2. GNP-LLO91–99 vaccine protects against listeriosis. DC vaccines were tested for ability to protect against listeriosis. (A) C57BL/6 mice were vaccinated once i.v with
various  DC vaccine vectors (1 × 106 cells) (DC-CONT, DC-LM lysate, DC-GAPDH1–22, DC-LLO91–99, DC-LLO189–201, DC-GNP-LLO91–99), soluble GNP-LLO91–99 (5 g/ml) or not
vaccinated (NV) (n = 5 mice/group) and 7 days later challenged i.v with 5 × 103 CFU of Listeria. Listeria counts in spleen homogenates expressed as CFU (mean ± SD) obtained
from  triplicate samples of three independent experiments (P < 0.01). Images corresponding to spleens and livers of non-vaccinated (NV) versus GNP-LLO91–99 vaccinated
mice  (GNP-LLO91–99). (B) Percentages of different spleen cell populations are shown: MØs, B cells, NK, CD4T cells, CD8T cells, DCi, DCm quantiﬁed in spleen homogenates
by  FACS. Results expressed as the mean ± SD of the percentage of positive cells (P < 0.05). (C) Levels of pro-inﬂammatory cytokines (MCP-1, TNF-, IFN-, IL-6, IL-10, IL-12)
were  analysed in mouse sera by CBA. Results expressed as cytokine concentration (pg/ml) of mean ± SD, P < 0.05.
1470 E. Rodriguez-Del Rio et al. / Vaccine 33 (2015) 1465–1473
Fig. 3. Effect of AdvaxTM adjuvant on GNP-LLO91–99 vaccine protection. (A) C57BL/6 mice were vaccinated i.p with DC-LLO91–99 or DC-GNP-LLO91–99 (1 × 106 cells), or soluble
GNP-LLO91–99 (5 g/ml) with or without Advax adjuvant (1 g/ml) or not vaccinated (NV) (n = 5 mice/vaccine vector). Seven days post-immunisation they were challenged
i.p  with 5 × 103 of Listeria (LMWT). Listeria counts in spleen homogenates 5 days post-challenge (CFU mean ± SD) of three independent experiments (P < 0.01). (B) Spleen
homogenates 5 days post-challenge were analysed by FACS (mean± SD of percentages of positive cells, P < 0.05). (C) Splenic DC from mice vaccinated as in A were analysed
to  quantitate CD11c+MHC-II+CD8+ DC (percentages of MHC-II+CD8+ positive cells (mean ± SD) of three different experiments, P < 0.05). (D) Serum cytokine levels 5 days
post-challenge in immunised mice (mean ± SD, P < 0.05). (E) Mice vaccinated as in (A) and challenged with 5 × 103 Listeria (LMWT). Spleen homogenates 5 days post-challenge
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.7. Advax-adjuvanted GNP-LLO91–99 increases splenic IL-12+
D8˛+ DC post-challenge
CD8+ DCs play a critical role in presentation of Listeria anti-
ens to protective CD4+ and CD8+ T cells and, in particular, in
L-12 production that correlates with protection [39,40]. We  there-
ore analysed splenic DC content, post-challenge. The frequency
f splenic CD8+ DC was almost doubled from 10% to 18% when
NP-LLO91–99 was formulated with AdvaxTM adjuvant (Fig. 3C).
his contrasted with a low frequency (2–3%) of CD8+ DC in the
pleen of non-vaccinated mice post-challenge. Notably, immun-
sation with free GNP-LLO91–99 plus AdvaxTM adjuvant generated
 higher frequency of splenic CD8+ DC than the DC vaccines
DC-GNP-LLO91–99 or DC-LLO91–99) (10%) (Fig. 3C). Hence, when
ormulated with AdvaxTM adjuvant, standard immunisation with
NP-LLO91–99 was as good or better than the more complex DC
accine approach at inducing splenic CD8+ DC that play a critical
ole in listeria protection
.8. Formulation of GNP-LLO91–99 vaccine with AdvaxTM
djuvant enhances Th1 cytokine responses
Since formulation of vaccines with AdvaxTM increased the fre-
uency of both CD8+ T cells and CD8+ DC in the spleen post-Listeria
hallenge, we next examined serum cytokine levels post-challenge
n splenocytes of mice immunised with or without AdvaxTM adju-
ant. Mice immunised with GNP-LLO91–99 plus AdvaxTM exhibited
igniﬁcantly greater MCP-1, TNF- and IFN- production when
ompared to mice immunised with GNP-LLO91–99 alone, consis-
ent with AdvaxTM driving an enhanced Th1-response against
isteria. Cytokine levels in mice immunised with GNP-LLO91–99
lus AdvaxTM were equivalent to those seen with the DC vac-
ine, DC-GNP-LLO91–99 (Fig. 3D, upper panel). Immunisation with
NP-LLO91–99 plus AdvaxTM was also associated with signiﬁcantly
reater splenocyte IL-12 and IL-10 production and reduced IL-6
roduction when compared to immunisation with GNP-LLO91–99
lone (Fig. 3D, lower panel), consistent with the AdvaxTM adjuvant
nhancing the Th1 response against Listeria.
.9. Formulation of GNP-LLO91–99 with AdvaxTM adjuvant
nhances IFN-producing Listeria-speciﬁc CD4+ and CD8+ T cells
Next, we evaluated the effect of AdvaxTM on the ability of
tandard immunisations with GNP-LLO91–99 to induce LLO-speciﬁc
D8+ and CD4+ T cells using IFN- as a Th1 subset marker. Five
ays post Listeria challenge, mice immunised with GNP-LLO91–99
lone had a detectable frequency (0.59%) of LLO91–99 speciﬁc IFN-
+ CD8+ T cells, but as expected had no responses against the CD4+
 cell epitope not contained in the vaccine (Fig. 3E, upper panel).
mmunisation with GNP-LLO91–99 plus AdvaxTM not only resulted
n a signiﬁcant increase in the frequency of LLO91–99 speciﬁc IFN-
+ CD8+ T cells (0.89%) but also resulted in the appearance of a
igniﬁcant number of IFN-+ CD4+ T cells recognising the CD4 epi-
ope, LLO189–201, not present in the vaccine (Fig. 3E, lower panel).
hus the Advax adjuvant enhanced the ability of the Listeria vac-
ine to prime for a process of T-cell epitope spreading in response
o Listeria infection.
To conﬁrm the above ﬁndings, the ability of AdvaxTM when
dded to either DC vaccines or free GNP-LLO91–99 vaccine to induce
LO91–99-speciﬁc CD8+ cells was tested using H2-Kb-LLO91–99
imers to label and identify the antigen-speciﬁc T cells (H2-Kd-
LO91–99 dimers were used with similar results, data not shown).
ere stimulated for 5 h with LLO91–99 or LLO189–201 peptides then intracellular cytokine sta
nd  frequency of these making IFN- producers (left plots) and the frequency of LLO91–99-s
ere  performed in triplicate and results are expressed as mean ± SD (p < 0.05).ine 33 (2015) 1465–1473 1471
Addition of AdvaxTM to GNP-LLO91–99 resulted in a 4-fold increase
in the frequency of LLO91–99-speciﬁc CD8+ cells versus GNP-
LLO91–99 vaccine alone, and was superior to all other vaccine for-
mulations including the DC vaccine, DC-GNP-LLO91–99 (Table 1, left
hand column). The effects of AdvaxTM were even more pronounced
when H2-Kb-LLO91–99 positive cells were gated for IFN-, with ∼10-
fold higher frequency of IFN- expressing H2-Kb-LLO91–99 positive
cells in mice vaccinated with GNP-LLO91–99 plus Advax versus mice
vaccinated with free GNP-LLO91–99 alone (Table 1, right hand col-
umn). This conﬁrmed that providing the vaccine included AdvaxTM
adjuvant, standard immunisation with GNP-LLO91–99 was superior
to all other vaccine approaches, including use of the best GNP-
loaded DC vaccine, at inducing Listeria-speciﬁc IFN-+ CD8+ T cells,
the critical cells involved in protection.
4. Discussion
The objective of this study was to identify an optimal vac-
cine formulation to protect against listerosis. Listeria protection is
largely dependent on CD4+ and CD8+ T cells rather than antibody-
mediated immunity [14,17]. Live vector vaccines are inherently
unsuitable for Listeria vaccines given their risk of causing serious
infection in immune-compromised individuals. As an alternative,
cellular DC-based vaccines where DC are loaded with Listeria anti-
gens ex vivo [6,11,19] and injected back into the host have been
proposed for induction of protective cellular immunity. We  ini-
tially designed a DC vaccine based on loading of DC with LLO91–99
peptide using conjugated GNP (GNP-LLO91–99) and showed that
this provided a high efﬁciency of DC loading, in vitro [22, 23]. DC-
GNP-LLO91–99 induced CD8+ T cell immunity in immunised mice
that translated into protection against Listeria challenge. However
DC vaccines are impractical and expensive to make, necessitating
that we  ﬁnd an alternative strategy for delivery of our GNP-based
vaccine. To overcome these problems, we next tested whether
standard immunisation with GNP-LLO91–99 rather than using it to
load DC in vitro, could target and load DC in vivo. However, only par-
tial protection was obtained by standard immunisation with free
GNP-LLO91–99 vaccine, inferior to that obtained with the DC vaccine.
To overcome this problem, we  next formulated the free GNP-
LLO91–99 antigen with AdvaxTM, a polysaccharide adjuvant shown
effective and safe in a broad range of animal models and human
trials [25–31,33–35]. In addition to a strong human safety record,
AdvaxTM was  selected based on its ability to induce robust CD4+
and CD8+ T cell responses [30,35]. As a proof of principle we ﬁrst
showed that AdvaxTM enhanced the immunogenicity of the DC vac-
cine, GNP-LLO91–99. This ﬁnding suggests Advax adjuvant may  offer
beneﬁts for DC vaccines for other indications such as cancer, where
the cost and complexity of DC vaccines is less an issue. However,
given our desire to move away from the DC vaccine approach for
Listeria, the most important ﬁnding was  that AdvaxTM signiﬁcantly
enhanced the immunogenicity of GNP-LLO91–99 when adminis-
tered as a standard vaccine. Notably, this translated into improved
Listeria protection to a level we had previously only achieved using
DC vaccines. The enhanced protection obtained with the Advax-
adjuvanted GNP-LLO91–99 vaccine was associated with an increased
frequency of splenic CD4+ and CD8+ T cells, NK cells and CD8+
DC. The latter have been reported to play a critical role in Listeria
protection via ability to produce IL-12 and activate IFN- produc-
ing CD4+ and CD8+ T cells [39,40]. Notably, immunisation with
Advax-adjuvanted GNP-LLO91–99 enhanced production of the Th1
cytokines, IL-12, IFN-, TNF-, and MCP-1, while reducing the Th2
cytokine, IL-6. Interestingly, immunisation with Advax-adjuvanted
ining performed. Histograms show the frequency of LLO189–201-speciﬁc CD4+ T cells
peciﬁc CD8+ T cells and frequency of these making IFN- (right plots). Experiments
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Tig. 4. Hypothetical model to explain the effect of AdvaxTM adjuvant on GNP-LLO91–99 p
ith  soluble GNP-LLO91–99 carriers in the presence or absence of AdvaxTM adjuva
escribed in text of the Section 4.
NP-LLO91–99 was also associated with increased production of
he anti-inﬂammatory cytokine, IL-10, but unlike other studies this
ncreased IL-10 was not associated with enhanced Listeria suscep-
ibility [32]. IL-10 may  normally act as an inverse marker of IFN-
roduction as IL-10 is downregulated by IL-12 and IFN- and vice
ersa. Because IL-12 and IFN- are dominant in determining Listeria
rotection and were both markedly increased by Advax-adjuvanted
NP-LLO91–99, the IL-10 even although increased would not be
xpected to block IFN--mediated protection in this situation,
ut may  actually have been beneﬁcial by reducing inﬂammatory
amage in response to Listeria infection. Immunisation with Advax-
djuvanted GNP-LLO91–99 resulted in an increased frequency of
LO91–99 speciﬁc IFN-+ CD8+ T cells, post-challenge. More surpris-
ng was the increased frequency of LLO189–201 speciﬁc IFN-+ CD4+
 cells, as this CD4+ epitope was not present in the vaccine the
ice received so these CD4+ T cells must have been generated in
esponse to the Listeria itself. This suggests that mice immunised
ith AdvaxTM adjuvant have a greater capacity for T-cell epitope
preading after Listeria challenge, thereby explaining the broader
-cell recognition of Listeria epitopes in the mice that received the
dvax-adjuvanted GNP-LLO91–99 vaccine.
Our model for how vaccination with Advax-adjuvanted GNP-
LO91–99 provides enhanced protection against listeriosis is
epicted in Fig. 4. In brief, injection of soluble GNP-LLO91–99 carri-
rs (step 1) targets the conjugated peptide to conventional splenic
C that are stimulated to a mature phenotype and can then prime
LO91–99-speciﬁc CD8+ T cells (step 3). Upon exposure to Listeria
step 2), these CD8+ T cells become activated and produce IFN-
 that in turn enhances DC IL-12 production and consequent NK
ell activation. A Th1 feedback loop is generated, which assists the
nduction of inﬂammatory and activated DC and MØ  that phago-
ytose and kill the bacteria (step 4). AdvaxTM adjuvant recruits
nd interacts with DC resulting in an increase in mature DC and,
n particular, CD8+ DC, which after loading with GNP-conjugated
LO91–99, migrate to the splenic white zones where they become
ctivated and induce expansion of LLO-speciﬁc CD4+ and CD8+
 cells (step 5). Upon exposure to Listeria,  these LLO-speciﬁcion against listeriosis. Diagram depicting predicted events when mice are vaccinated
ep 1) and then challenged with live Listeria (step 2). Explanation of the model is
CD8+ T cells become activated and induce high levels of IFN-,
IL-12, MCP-1, and TNF-. These Th1 cytokines enhance Listeria
phagocytosis and destruction, while increased IL-10 may  help pre-
vent excess inﬂammation (step 6). CD8+ T cells generated by the
Advax-adjuvanted vaccine enhance epitope spreading by inducing
DC to express additional Listeria epitopes, thereby allowing recruit-
ment of additional CD4+ T cells able in response to these MHC-II
epitopes. This promotes further expansion and activation of LLO-
speciﬁc T cells including IFN- producing LLO189–201-speciﬁc CD4+
T cells (step 7) that synergise with IFN--producing CD8+ T cells in
Listeria control.
Overall, these results support further development of GNP-
peptide carriers together with AdvaxTM adjuvant as a vaccine
platform with potential applicability to prophylactic immunisation
against Listeria,  plus other broader uses.
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